New hope for tough leukemia? tiny trial tests targeted pill
NCT ID NCT07604064
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an oral drug called olutasidenib in 3 Japanese patients whose acute myeloid leukemia (AML) has a specific IDH1 gene mutation and has not responded to or returned after other treatments. The main goal is to check safety, but researchers will also see if the drug can bring about a remission. Because it is a very small, early-phase trial, the results are preliminary and may not apply to all patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olutasidenib (a targeted drug taken by mouth)
- What this could lead to
- If it works, this could point toward a treatment option for people with a specific genetic type of leukemia that has come back or not responded to other therapies.
- What could go wrong
- This is a very small, early-phase study with only 3 Japanese participants, so results may not apply broadly. The drug may not work or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY IDH1 MUTATION-POSITIVE ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
RECRUITINGTokyo and Other Japanese Cities, Japan